Miragen Therapeutics Inc (MGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH279932D
- Pages: 73
- November 2018
- Total Views:1118
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), Adult T-Cell Lymphoma/Leukemia, Diffuse Large-B Cell Lymphoma, Chronic Lymphocytic Leukemia, ALS, Heart Failure, Incisional Complications, Cutaneous Fibrosis, Idiopathic Pulminary Fibrosis and Other Fibrotic Indications. The pipeline development is focused on microRNA platform that regulate gene expression and influences the pathways responsible for many disease processes. Miragen is headquartered in Boulder, Colorado, the US.
Miragen Therapeutics Inc (MGEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
miRagen Therapeutics Raises USD8 Million in Financing 13
miRagen Therapeutics Raises USD41 Million in Series C Financing 14
miRagen Therapeutics Raises USD 20 Million In Series B Financing 16
Partnerships 17
miRagen Therapeutics Enters into Agreement with Leukemia & Lymphoma Society 17
Merger 18
Signal Genetics Merges with miRagen Therapeutics 18
Licensing Agreements 20
Santaris Pharma Amends Licensing Agreement With miRagen Therapeutics 20
miRagen Therapeutics Enters Into Licensing Agreement With University of Glasgow 21
Equity Offering 22
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 22
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 24
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 25
Debt Offering 27
miRagen Therapeutics Raises USD8.5 Million in Private Placement of Notes 27
Miragen Therapeutics Inc-Key Competitors 28
Miragen Therapeutics Inc-Key Employees 29
Miragen Therapeutics Inc-Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 07, 2018: miRagen Therapeutics reports third quarter 2018 financial results and provides corporate update 31
Aug 07, 2018: miRagen Therapeutics announces second quarter 2018 financial results 33
May 09, 2018: miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 35
Mar 14, 2018: miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 37
Nov 08, 2017: miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 39
Aug 11, 2017: miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 41
May 10, 2017: miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 43
Mar 31, 2017: miRagen Therapeutics Provides Corporate Update 45
Corporate Communications 46
Jan 05, 2018: miRagen Therapeutics Expands Board of Directors With Appointment of Arlene Morris 46
Product Approvals 47
May 24, 2017: miRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma 47
Mar 31, 2017: miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides 48
Clinical Trials 49
Jul 10, 2018: miRagen begins Phase ll trial of MRG-201 for keloid 49
May 02, 2018: miRagen Therapeutics Presents New Preclinical Data Supporting use of MicroRNA-Targeted Therapies for Ophthalmic Diseases 50
Apr 19, 2018: miRagen Therapeutics to Present Preclinical Data on MRG-201 at the Association for Research in Vision and Ophthalmology Annual Meeting 52
Mar 27, 2018: miRagen Announces Initiation of Phase 1 Clinical Trial of MRG-110 53
Feb 02, 2018: miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial of MRG-106 in Mycosis Fungoides at the T-Cell Lymphoma Forum 54
Jan 24, 2018: miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum 56
Dec 11, 2017: miRagen Therapeutics Presents New Interim Clinical Data Expanding on Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at 2017 American Society of Hematology Annual Meeting 57
Nov 01, 2017: miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the 2017 American Society of Hematology Annual Meeting 59
Oct 18, 2017: miRagen Therapeutics Announces Presentations on Lead Product Candidate MRG-106 at the DIA Oligonucleotide-Based Therapeutics Conference 60
Oct 18, 2017: miRagen Therapeutics Announces Presentations on Lead Product Candidate MRG-201 at the DIA Oligonucleotide-Based Therapeutics Conference 61
Oct 13, 2017: miRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at EORTC Global Task Force Meeting 62
Sep 11, 2017: miRagen Therapeutics Presents New MRG-201 Preclinical Data for Inhaled MicroRNA-29 Mimic Targeting Pulmonary Fibrosis 64
Sep 01, 2017: Miragen Therapeutics to Present New MRG-201 Preclinical Inhalation Data for Pulmonary Fibrosis at the European Respiratory Society International Congress 65
Jun 08, 2017: miRagen Presents Development Update of its Clinical Product Candidate MRG-110 66
Jun 08, 2017: miRagen Therapeutics Presents Update on Development of Clinical Product Candidate MRG-201 67
Jun 08, 2017: miRagen Therapeutics to Present MRG-106 Phase 1 Clinical Trial Data at the International Conference on Malignant Lymphoma 68
Jun 05, 2017: miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial Evaluating MRG-106 in Subjects with Mycosis Fungoides 69
May 17, 2017: miRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, at the American Society of Clinical Oncology Annual Meeting 70
Apr 27, 2017: miRagen Therapeutics Presents Interim Results from MRG-201 Phase 1 Clinical Trial Demonstrating Pharmacodynamic Activity in Human Skin Incisions 71
Apr 20, 2017: miRagen Therapeutics to Present MRG-201 Data at the Society for Investigative Dermatology Annual Meeting 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
List Of Figure
List of Figures
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
miRagen Therapeutics Raises USD8 Million in Financing 13
miRagen Therapeutics Raises USD41 Million in Series C Financing 14
miRagen Therapeutics Raises USD 20 Million In Series B Financing 16
miRagen Therapeutics Enters into Agreement with Leukemia & Lymphoma Society 17
Signal Genetics Merges with miRagen Therapeutics 18
Santaris Pharma Amends Licensing Agreement With miRagen Therapeutics 20
miRagen Therapeutics Enters Into Licensing Agreement With University of Glasgow 21
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 22
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 24
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 25
miRagen Therapeutics Raises USD8.5 Million in Private Placement of Notes 27
Miragen Therapeutics Inc, Key Competitors 28
Miragen Therapeutics Inc, Key Employees 29
Miragen Therapeutics Inc, Subsidiaries 30
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Miragen Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), Adult T-Cell Lymphoma/Leukemia, Diffuse Large-B Cell Lymphoma, Chronic Lymphocytic Leukemia, ALS, Heart Failure, Incisional Complications, Cutaneous Fibrosis, Idiopathic Pulminary Fibrosis and Other Fibrotic Indications. The pipeline development is focused on microRNA platform that regulate gene expression and influences the pathways responsible for many disease processes. Miragen is headquartered in Boulder, Colorado, the US.
Miragen Therapeutics Inc (MGEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
miRagen Therapeutics Raises USD8 Million in Financing 13
miRagen Therapeutics Raises USD41 Million in Series C Financing 14
miRagen Therapeutics Raises USD 20 Million In Series B Financing 16
Partnerships 17
miRagen Therapeutics Enters into Agreement with Leukemia & Lymphoma Society 17
Merger 18
Signal Genetics Merges with miRagen Therapeutics 18
Licensing Agreements 20
Santaris Pharma Amends Licensing Agreement With miRagen Therapeutics 20
miRagen Therapeutics Enters Into Licensing Agreement With University of Glasgow 21
Equity Offering 22
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 22
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 24
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 25
Debt Offering 27
miRagen Therapeutics Raises USD8.5 Million in Private Placement of Notes 27
Miragen Therapeutics Inc-Key Competitors 28
Miragen Therapeutics Inc-Key Employees 29
Miragen Therapeutics Inc-Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 07, 2018: miRagen Therapeutics reports third quarter 2018 financial results and provides corporate update 31
Aug 07, 2018: miRagen Therapeutics announces second quarter 2018 financial results 33
May 09, 2018: miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 35
Mar 14, 2018: miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 37
Nov 08, 2017: miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 39
Aug 11, 2017: miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 41
May 10, 2017: miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 43
Mar 31, 2017: miRagen Therapeutics Provides Corporate Update 45
Corporate Communications 46
Jan 05, 2018: miRagen Therapeutics Expands Board of Directors With Appointment of Arlene Morris 46
Product Approvals 47
May 24, 2017: miRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma 47
Mar 31, 2017: miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides 48
Clinical Trials 49
Jul 10, 2018: miRagen begins Phase ll trial of MRG-201 for keloid 49
May 02, 2018: miRagen Therapeutics Presents New Preclinical Data Supporting use of MicroRNA-Targeted Therapies for Ophthalmic Diseases 50
Apr 19, 2018: miRagen Therapeutics to Present Preclinical Data on MRG-201 at the Association for Research in Vision and Ophthalmology Annual Meeting 52
Mar 27, 2018: miRagen Announces Initiation of Phase 1 Clinical Trial of MRG-110 53
Feb 02, 2018: miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial of MRG-106 in Mycosis Fungoides at the T-Cell Lymphoma Forum 54
Jan 24, 2018: miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum 56
Dec 11, 2017: miRagen Therapeutics Presents New Interim Clinical Data Expanding on Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at 2017 American Society of Hematology Annual Meeting 57
Nov 01, 2017: miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the 2017 American Society of Hematology Annual Meeting 59
Oct 18, 2017: miRagen Therapeutics Announces Presentations on Lead Product Candidate MRG-106 at the DIA Oligonucleotide-Based Therapeutics Conference 60
Oct 18, 2017: miRagen Therapeutics Announces Presentations on Lead Product Candidate MRG-201 at the DIA Oligonucleotide-Based Therapeutics Conference 61
Oct 13, 2017: miRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at EORTC Global Task Force Meeting 62
Sep 11, 2017: miRagen Therapeutics Presents New MRG-201 Preclinical Data for Inhaled MicroRNA-29 Mimic Targeting Pulmonary Fibrosis 64
Sep 01, 2017: Miragen Therapeutics to Present New MRG-201 Preclinical Inhalation Data for Pulmonary Fibrosis at the European Respiratory Society International Congress 65
Jun 08, 2017: miRagen Presents Development Update of its Clinical Product Candidate MRG-110 66
Jun 08, 2017: miRagen Therapeutics Presents Update on Development of Clinical Product Candidate MRG-201 67
Jun 08, 2017: miRagen Therapeutics to Present MRG-106 Phase 1 Clinical Trial Data at the International Conference on Malignant Lymphoma 68
Jun 05, 2017: miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial Evaluating MRG-106 in Subjects with Mycosis Fungoides 69
May 17, 2017: miRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, at the American Society of Clinical Oncology Annual Meeting 70
Apr 27, 2017: miRagen Therapeutics Presents Interim Results from MRG-201 Phase 1 Clinical Trial Demonstrating Pharmacodynamic Activity in Human Skin Incisions 71
Apr 20, 2017: miRagen Therapeutics to Present MRG-201 Data at the Society for Investigative Dermatology Annual Meeting 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
List Of Figure
List of Figures
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
miRagen Therapeutics Raises USD8 Million in Financing 13
miRagen Therapeutics Raises USD41 Million in Series C Financing 14
miRagen Therapeutics Raises USD 20 Million In Series B Financing 16
miRagen Therapeutics Enters into Agreement with Leukemia & Lymphoma Society 17
Signal Genetics Merges with miRagen Therapeutics 18
Santaris Pharma Amends Licensing Agreement With miRagen Therapeutics 20
miRagen Therapeutics Enters Into Licensing Agreement With University of Glasgow 21
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 22
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 24
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 25
miRagen Therapeutics Raises USD8.5 Million in Private Placement of Notes 27
Miragen Therapeutics Inc, Key Competitors 28
Miragen Therapeutics Inc, Key Employees 29
Miragen Therapeutics Inc, Subsidiaries 30
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Miragen Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020